BioScrip Commences Patient Enrollment in Teva Neuroscience, Inc. Therapy Optimization in Multiple Sclerosis (Tops MS) Research Study

Published: Jun 30, 2009

ELMSFORD, N.Y.--(BUSINESS WIRE)--BioScrip, Inc. (Nasdaq: BIOS) announced today that Teva Neuroscience tapped BioScrip Specialty Pharmacy as one of several national research study participants in one of the most comprehensive MS research studies announced to date.

Back to news